| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
|
| | CNTO 148 Basic information |
| Product Name: | CNTO 148 | | Synonyms: | CNTO 148;Simponi;Research Grade Golimumab (DHB94404);Research Grade Golimumab;MK-8259|||SCH 900259|||CNTO-148;Golimumab BRP;Golimumab CRS;Golimumab | | CAS: | 476181-74-5 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![CNTO 148 Structure]() |
| | CNTO 148 Chemical Properties |
| storage temp. | Store at -20°C | | form | Liquid | | color | Colorless to light yellow |
| | CNTO 148 Usage And Synthesis |
| Description | The proinflammatory cytokine tumor necrosis factor-alpha (TNF-α) has
been implicated as the primary mediator of articular inflammation in
diseases such as RA, PsA, and AS. Targeting TNF-a has been a successful
strategy in the intervention of a range of immunoinflammatory disorders.
Biologics have risen to the forefront of TNF-α blockade with infliximab, a
chimeric monoclonal antibody (mAb), and etanercept, a fusion protein
comprised of the ligand-binding segment of the soluble TNF receptor,
reaching the market in the late 1990s for the initial indication of RA. Since
then, their use has expanded to other diseases of inflammatory etiology,
and two additional TNF-α inhibitors have joined the competition.
Golimumab, a
human anti-TNF-α mAb that binds to both soluble and transmembrane
forms of TNF-a, is the first once-monthly subcutaneous agent to enter the
market and is currently approved for the treatment of RA in combination
with methotrexate (MTX), PsA alone or in combination with MTX, and AS.
. | | Originator | Centocor Ortho
Biotech (US) | | Uses | Treatment of allergic asthma. | | Brand name | Simponi | | Side effects | The most common adverse reactions,
occurring with an incidence >5%, were upper respiratory tract infection
and nasopharyngitis. Regarding drug interactions, live vaccines should not be administered while being treated with golimumab. As an increased
risk of serious infection has been associated with concomitant use
of abatacept and anakinra, combination of these drugs is not recommended.
Also, golimumab treatment should not be initiated in patients
with an active infection. Furthermore, patients should be warned about the
higher incidence of malignancies observed with anti-TNF-a therapy and
increased risks of worsening or new onset of heart failure, of exacerbation
or new onset of demyelinating disease, and of hepatitis B reactivation. |
| | CNTO 148 Preparation Products And Raw materials |
|